Sudo raises $30M more to advance TYK2 inhibitor therapies to trials
Sudo Biosciences has secured an additional $30 million in funding to support the development of two TYK2 inhibitor therapies for multiple sclerosis (MS) and other neurological and skin conditions ā and now is aiming to launch clinical trials later this year. With a second close of its Series…